Stuart J. Swiedler, MD, Ph.D.

Dr. Swiedler is a biotechnology consultant with more than 25 years of experience in the biotechnology field, primarily as a scientist and executive at Glycomed, Inc., and as a clinical scientist and senior executive at BioMarin Pharmaceutical Inc. During his 10-year period at BioMarin, he contributed to the non-clinical and clinical aspects of drug development for the regulatory approvals of the orphan drugs Aldurazyme, Naglazyme and Kuvan. He continues to focus on orphan drug products and providing his clinical expertise to biotech companies and investment firms. He received his B.S. from the University at Albany, and his MD and Ph.D. from the Johns Hopkins University School of Medicine. He completed a residency program in Anatomic Pathology at Yale University School of Medicine and Duke University School of Medicine, and a post-doctoral fellowship at Duke.